Composition
Each film coated tablet contains:
Valsartan and Hydrochlorothiazide
Co-vasotec 80/12.5 mg Film coated Tablets: Film coated tablets containing 80 mg Valsartan and 12.5 mg Hydrochlorothiazide.
Co-vasotec 160/12.5 mg Film coated Tablets: Film coated tablets containing 160 mg Valsartan and 12.5 mg Hydrochlorothiazide.
Co-vasotec 160/25 mg Film coated Tablets: Film coated tablets containing 160 mg Valsartan and 25 mg Hydrochlorothiazide.
Inactive ingredients:
Co-vasotec 80/12.5 mg & 160/12.5 mg F.C. Tablets: Microcrystalline cellulose PH101, Povidone K25, colloidal silicon dioxide, crosscarmellose sodium, microcrystalline cellulose PH102, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol 400, polyethylene glycol 6000, titanium dioxide, iron oxide red, iron oxide yellow.
Co-vasotec 160/25 mg F.C. Tablets: Microcrystalline cellulose PH101, Povidone K25, colloidal silicon dioxide, crosscarmellose sodium, microcrystalline cellulose PH102, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol 400, polyethylene glycol 6000, titanium dioxide, iron oxide yellow.

Therapeutic Indications
Co-vasotec (valsartan and hydrochlorothiazide (HCTZ), USP) is indicated for the treatment of hypertension.
Co-vasotec may be used in patients whose blood pressure is not adequately controlled on monotherapy.
Co-vasotec may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Co-vasotec as initial therapy for hypertension should be based on an assessment of potential benefits and risks.
Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy.
Individual blood pressure goals may vary based upon the patient's risk.
Data from the high dose multifactorial trial provides estimates of the probability of reaching a target blood pressure with valsartan and hydrochlorothiazide compared to valsartan or hydrochlorothiazide monotherapy.
For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likekhood of achieving a goal of < 140 mmHg (systolic) and 60% likelihood of achieving < 90 mmHg (diastolic) with valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals with valsartan and hydrochlorothiazide rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic).

Dosage and Administration
The recommended dose is one tablet of Co-vasotec 80/12.5 per day.
In the event of an inadequate response after treatment for 3-4 weeks, it may be necessary to continue treatment with one Co-vasotec 160/25 tablet daily. Use of Co-vasotec 160/25 tablet (1 Co-vasotec 160/25 tablet per day) is restricted to those patients in whom adequate reduction of blood pressure is not achieved with Co-vasotec 160/12.5 tablet. The maximum antihypertensive effect is seen within 2-4 weeks.
Co-vasotec can be taken independently of meal times. It should be swallowed with liquid.
Co-vasotec can be taken by patients of any age.
Dose adjustment is not necessary in patient with mild to moderate renal failure (creatinine clearance ≥ 30 ml/min) or mild to moderate hepatic failure (see Warnings and Precautions).
There is insufficient experience of the therapeutic use of valsartan+hydrochlorothiazide in children and adolescents